Selecta Biosciences receives malaria research grant from Bill & Melinda Gates Foundation

Selecta Biosciences received a $1.25 million grant from the Bill & Melinda Gates Foundation on Tuesday to support research on a novel dual action, immune-activating Synthetic Vaccine Particle (SVP) for malaria.

Selecta Biosciences is a clinical stage biotechnology company working with immune modulating nanomedicines to create targeted antigen-specific immune responses for the prevention and treatment of diseases.

The company designed SVP technology that could potentially protect against malaria by fighting early infection and blocking transmission via infected mosquitoes. The technology is designed to individually optimize biodegradable nanoparticles to fight multiple antigens while also releasing immune boosting adjuvants to relevant immune cells.

Selecta's lead formulation for malaria was designed and selected based on a demonstrated ability to outperform benchmarks in antibody levels and protection in preclinical rodent studies.

"Working with a global leader in vaccines, such as the Bill & Melinda Gates Foundation, will allow us to maximize our platform's capabilities in the next stage of preclinical studies, in which we aim to show proof of concept for robust and durable responses to two diverse targets relevant to malaria," Werner Cautreels, the president and CEO of Selecta Biosciences, said. "This collaboration accelerates our ability to evaluate our technology to treat a range of diseases that impact human health."